T2022 Prevalence and Incidence Screening in a Population-Based FOBT Colorectal Screening Programme

2009 ◽  
Vol 136 (5) ◽  
pp. A-622
Author(s):  
Ioanna Kostourou ◽  
Paula L. McClements ◽  
Gillian Libby ◽  
Frank A. Carey ◽  
Callum G. Fraser ◽  
...  
2009 ◽  
Vol 136 (5) ◽  
pp. A-626
Author(s):  
Ioanna Kostourou ◽  
Paula L. McClements ◽  
Gillian Libby ◽  
Frank A. Carey ◽  
Callum G. Fraser ◽  
...  

2009 ◽  
Vol 136 (5) ◽  
pp. A-769
Author(s):  
Ioanna Kostourou ◽  
Paula L. McClements ◽  
Gillian Libby ◽  
Frank A. Carey ◽  
Callum G. Fraser ◽  
...  

2020 ◽  
Author(s):  
MH Núñez-Rodriguez ◽  
PD Redondo ◽  
F Riu ◽  
M Cimavilla ◽  
RS Ocaña ◽  
...  

2017 ◽  
Vol 25 (3) ◽  
pp. 155-161 ◽  
Author(s):  
Sameer Bhargava ◽  
Kaitlyn Tsuruda ◽  
Kåre Moen ◽  
Ida Bukholm ◽  
Solveig Hofvind

Objective The Norwegian Breast Cancer Screening Programme invites women aged 50–69 to biennial mammographic screening. Although 84% of invited women have attended at least once, attendance rates vary across the country. We investigated attendance rates among various immigrant groups compared with non-immigrants in the programme. Methods There were 4,053,691 invitations sent to 885,979 women between 1996 and 2015. Using individual level population-based data from the Cancer Registry and Statistics Norway, we examined percent attendance and calculated incidence rate ratios, comparing immigrants with non-immigrants, using Poisson regression, following women's first invitation to the programme and for ever having attended. Results Immigrant women had lower attendance rates than the rest of the population, both following the first invitation (53.1% versus 76.1%) and for ever having attended (66.9% versus 86.4%). Differences in attendance rates between non-immigrant and immigrant women were less pronounced, but still present, when adjusted for sociodemographic factors. We also identified differences in attendance between immigrant groups. Attendance increased with duration of residency in Norway. A subgroup analysis of migrants' daughters showed that 70.0% attended following the first invitation, while 82.3% had ever attended. Conclusions Immigrant women had lower breast cancer screening attendance rates. The rationale for immigrant women's non-attendance needs to be explored through further studies targeting women from various birth countries and regions.


Author(s):  
Luca Alessandro Carbonaro ◽  
Sighelgaita Sonia Rizzo ◽  
Simone Schiaffino ◽  
Anna Pisani Mainini ◽  
Nicole Berger ◽  
...  

1997 ◽  
Vol 4 (3) ◽  
pp. 142-146 ◽  
Author(s):  
G Castiglione ◽  
M Zappa ◽  
G Grazzini ◽  
C Sani ◽  
A Mazzotta ◽  
...  

Objective— To compare the costs of colorectal cancer (CRC) screening by two faecal occult blood tests (FOBT)—namely, Hemoccult (guaiac based) and reversed passive haemagglutination (RPHA) tests. RPHA was interpreted according to two positivity thresholds (+ or +/-). Methods— Attenders performed both tests. Subjects with a positive FOBT test were invited to have a complete exploration of the colon. The total costs for every 10 000 screened subjects and costs for each unit of result (screened subject, or patient with adenoma/s or cancer detected) were calculated for both tests. Results— 8353 subjects were enrolled. A total of 2109 repeated screening after two years. RPHA(+ and +/-) showed the highest and RPHA(+) the lowest positivity rate at first screening. The Hemoccult positivity rate was highest at repeat screening. Total costs of screening by RPHA(+ and +/-) were highest as this method had the highest recall rate. Screening by RPHA(+) was the least costly. Costs for each screened subject were highest for RPHA(+ and +/-) and lowest for RPHA(+). Costs for each cancer detected were lowest for RPHA(+) and highest for Hemoccult or RPHA(+ and +/-) in subjects aged > 49 or < 50, respectively. Costs for subjects with detected adenoma/s of > 9 mm were lowest for RPHA(+ and +/-) and highest for Hemoccult. At repeat screening total costs of RPHA(+ and +/-) were lower than at first screening, whereas for each subject with cancer or adenoma/s costs were increased. Conclusions— Our data confirm that screening by RPHA is more cost effective than by Hemoccult.


Sign in / Sign up

Export Citation Format

Share Document